Recent HIV/AIDS News from NIAID, NIH, and FDA

December 18, 2013: Animal Vaccine Study Yields Insights That May Advance HIV Vaccine Research “A vaccine study in monkeys designed to identify measurable signs that the animals were protected from infection by SIV, the monkey version of HIV, as well as the mechanism of such protection has yielded numerous insights that may advance HIV vaccine research.” Read the NIAID press release.   December 17, 2013: NIH Names Leadership, Research Units for Restructured HIV/AIDS Clinical Trials Networks “Principal investigators and clinical trials units (CTUs) have been chosen to lead and conduct the research of five HIV/AIDS clinical trials networks through 2021. The effort is directed and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.” Read the NIH press release.   December 13, 2013: Changes to Complera (Emtricitabine, Rilpivirine, Tenofovir Disoproxil Fumarate) Labeling “On December 13, 2013, FDA approved changes to the Complera (emtricitabine, rilpivirine, tenofovir disoproxil fumarate) label to include the use of Complera for the treatment of HIV-1 infection in certain adult patients who are virologically suppressed on a stable ritonavir-boosted protease inhibitor regimen.” Read the FDA announcement and view the AIDSinfo patient fact sheet on Complera.